Fluidigm, which makes high-throughput sequencing devices and consumables for genetic labs, will see its quiet period end on Monday, March 21. On February 9, the company raised $75 million by offering 5.6 million shares at $13.50, at the low end of the range of $13.50 to $15.50. Deutsche Bank Securities and Piper Jaffray acted as lead managers on the deal.
